hepatitis C
Sovaldi performs for Gilead
April 24, 2014Sales and Marketing Gilead, HCV, Q1, hepatitis C, sovaldi
Gilead Sciences’ once-daily, oral hepatitis C treatment Sovaldi has returned better than expected figures in the first quarter of the …
Patient death halts BMS hep C trial
August 30, 2012Sales and Marketing BMS, HCV, hepatitis C
Bristol-Myers Squibb has admitted that the death of a patient was behind its decision to stop development of a potential …
Bristol-Myers Squibb halts Hep C pill study
August 2, 2012Research and Development, Sales and Marketing BMS, hepatitis C, pill, trial suspension
Bristol-Myers Squibb has halted a mid-stage trial of a new Hepatitis C drug due to major safety concerns. In a …
Gilead aims for hep C lead with Pharmasset acquisition
November 22, 2011Research and Development Gilead, HCV, Pharmasset, Victrelis, hepatitis C
Gilead Sciences is to buy Pharmasset for $11 billion in a bid to become a leader in hepatitis C treatment.The …
Boehringer hails hepatitis C candidate
November 9, 2011Sales and Marketing BI201335, Boehringer Ingelheim, HCV, Incivo, Victrelis, hepatitis C
Boehringer Ingelheim believes that one of its investigational drugs for liver disease hepatitis C (HCV) could shorten patients’ treatment time …
Roche buys US firm Anadys for $230 million
October 17, 2011Research and Development, Sales and Marketing Roche, hepatitis C
Roche has acquired US firm Anadys for $230 million, bolstering its infectious drugs pipeline. California-based Anadys develops oral, small molecule …
Boehringer signs away HIV rights to focus on hep C
October 7, 2011Research and Development Boehringer, Gilead, HIV, hepatitis C
Boehringer Ingelheim has signed a deal giving Gilead Sciences exclusive worldwide rights to a major part of its HIV portfolio. …
Merck and Roche extend Victrelis co-promotion deal to Europe
July 22, 2011Sales and Marketing Merck & Co, Roche, Victrelis, hepatitis C
Merck & Co is ramping up efforts to push its new hepatitis C treatment Victrelis to the fore, signing a …
Hep C drug Victrelis gains EU approval
July 20, 2011Sales and Marketing Incivek, Victrelis, hepatitis C
Merck Sharp & Dohme’s Victrelis, one of two major new hepatitis C drugs, has gained final approval in Europe. Victrelis …
Hepatitis C rivals go head to head
July 19, 2011Sales and Marketing Incivek, Incivo, Victrelis, boceprevir, hepatitis C, telaprevir
The field of hepatitis C treatment has two new groundbreaking medicines to treat the condition.Merck’s Victrelis (boceprevir) and Johnson & …
J&J and Vertex’s hep C drug Incivek approved by FDA
May 24, 2011Sales and Marketing FDA, Incivek, Johnson & Johnson, Vertex, hepatitis C, telaprevir
The FDA has approved Johnson & Johnson/Vertex’s new oral hepatitis C drug Incivek. Incivek (telaprevir), a protease inhibitor, is now …
Merck and Roche sign hepatitis C co-promotion deal
May 18, 2011Medical Communications, Sales and Marketing Merck, Roche, hepatitis C
Merck & Co and Roche have signed an agreement that will see them co-promote each other’s hepatitis C drugs in …
Merck’s hepatitis drug Victrelis approved by FDA
May 16, 2011Sales and Marketing Merck & Co, Victrelis, boceprevir, hepatitis C
The FDA has approved Merck’s hepatitis C drug Victrelis, the first oral treatment for the disease. Victrelis (boceprevir) has been …
Boehringer begins late-stage hep C trial
April 27, 2011Research and Development BI 201335, Boehringer Ingelheim, hepatitis C
Boehringer Ingelheim has begun enrolling patients in North America for a phase III trial of its chronic hepatitis C virus …
New BMS drug trumps peg-interferon alpha
April 4, 2011Research and Development, Sales and Marketing BMS, EASL, hepatitis C, pegintron alfa
Bristol-Myers Squibb has been given a boost by trial results which suggest its compound for hepatitis C, PEG-Interferon lambda, is …
Latest content
FibroFind appoints Lee Borthwick as CEO
